Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Archer-Daniels-Midland Company

Aflac

Dover

Emerson Electric

General Dynamics

Pentair

If there's anything better than having at least some exposure to passive income-providing enterprises, it's loading the boat on the most undervalued dividend aristocrats to buy. Per Investopedia, “[d]ividend aristocrats are stocks of companies that have raised their dividends for at least 25 consecutive years.

The 7 Most Undervalued Dividend Aristocrats to Buy

AbbVie Inc. (NYSE: ABBV) stock is back to where it started after the day after posting a mixed fourth-quarter earnings report. The company delivered a slight beat on expected earnings but came in light on the top line.

AbbVie Has a Mixed Outlook After Mixed Earnings

Apple

Abbott Labs

Accenture Plc

Agree Realty

Ameren

AGCO

Apartment Income REIT Corp

Applied Industrial Technologies

ALLETE

Allegion

Ally Financial

Amgen

A. O. Smith

Apogee Enterprises

Ames National

Atmos Energy

Avista

American States Water

Bar Harbor Bankshares

Brown & Brown

Cable One

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.

Dividend Champion, Contender, And Challenger Highlights: Week Of February 12

Automatic Data Processing

Albemarle

Amcor Plc

Air Products and Chemicals

Becton, Dickinson and Co.

Franklin Resources

Cardinal Health

Caterpillar

Chubb

Church & Dwight

C.H. Robinson Worldwide

Cincinnati Financial

Colgate-Palmolive

Clorox

Cintas Corp

Chevron

Ecolab

The annual rebalancing and subsequent changes to the S&P 500 Dividend Aristocrats Index have produced a new list of 67 dividend growth stocks called the Dividend Aristocrats. I rank the Dividend Aristocrats using Quality Snapshots, an elegant and effective system for assessing the quality of dividend growth stocks.

The Dividend Aristocrats Ranked By Quality Scores

Digital Realty Trust

iShares MSCI EAFE Growth ETF

iShares MSCI EAFE Value ETF

Fastenal

Home Depot

Johnson & Johnson

Kimberly-Clark

Lockheed Martin

McDonald's

Altria

Nuveen Build America Bond Fund

NextEra Energy

iShares Preferred and Income Securities ETF 

Invesco QQQ

Cohen & Steers Quality Income Realty Fund

iShares 1-3 Year Treasury Bond ETF

Proshares Short 20+ Year Treasury

iShares 20+ Year Treasury Bond ETF

Texas Instruments

Reaves Utility Income Fund

Vanguard Dividend Appreciation ETF

Vanguard High Dividend Yield ETF

We will go over our thesis as to how a diversified income method with low volatility could make you financially independent. We regularly write about multi-basket income strategies with an in-built hedging mechanism to keep the drawdowns to a minimum. They provide not only consistent income but also long-term growth with 30% less volatility.

How This Income Method Could Lead To Financial Freedom

Don't think the challenges for Humira doom AbbVie to a sub-par stock performance this year.

Here's Exactly How AbbVie Stock Can Beat the Market In 2023

We share another of the 22 Mega Cap stocks with the prospect of higher prices in 2023. Lyn Alden provides important insight into the fundamental terrain on which AbbVie Inc. currently sits.

AbbVie: A 4% Yield Plus Potential Upside - What's Not To Like?

AbbVie stock won at least one upgrade Friday after issuing long-awaited guidance for Humira for the first year it faces new competition. The post AbbVie's Humira: The Downfall Won't Be As 'Draconian' As Initially Expected appeared first on Investor's Business Daily.

AbbVie's Humira: The Downfall Won't Be As 'Draconian' As Initially Expected

While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, AbbVie (ABBV) Q4 Earnings: A Look at Key Metrics

AbbVie Inc. (NYSE:ABBV ) Q4 2022 Earnings Conference Call February 9, 2023 9:00 AM ET Company Participants Liz Shea - Vice President of Investor Relations Rick Gonzalez - Chairman & Chief Executive Officer Jeff Stewart - Executive Vice President & Chief Commercial Officer Carrie Strom - Senior Vice President & President of Allergan Aesthetics Tom Hudson - Senior Vice President of R&D & Chief Scientific Officer Rob Michael - Vice Chairman & President Scott Reents - Senior Vice President & Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Terence Flynn - Morgan Stanley Chris Schott - JPMorgan Gary Nachman - BMO Capital Markets Carter Gould - Barclays Steve Scala - Cowen Tim Anderson - Wolfe Research Chris Shibutani - Goldman Sachs Colin Bristow - UBS Geoff Meacham - Bank of America Robyn Karnauskas - Truist Simon Baker - Redburn Navann Ty - BNP Parabas Gavin Clark-Gartner - Evercore ISI Operator Good morning. Thank you for standing by.

AbbVie Inc. (ABBV) Q4 2022 Earnings Call Transcript

The drugmaker is offering steep discounts on its immune-disease therapy Humira to protect market share this year.

The End of Abbvie's $200 Billion Monopoly Won't Sink the Stock

PepsiCo

Philip Morris

Are these the best dividend stocks to buy today?

What Stocks to Buy Today? 3 Dividend Stocks To Watch After Earnings

News for AbbVie Stock (ABBV)